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Abstract
Introduction: The aim of the present study was to assess the prevalence and characteristics of subclinical arthritis
of carpal and metacarpophalangeal joints in patients with systemic sclerosis (SSc).
Methods: Low-field (0.2 T) magnetic resonance imaging (MRI) was performed in consecutive patients with SSc
attending our center between January 2010 and March 2011. Results were assessed in a standardized manner
using the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) and standardized assessments of all
hand joints. Patients with arthritis due to overlap syndromes were excluded.
Results: Of 38 inpatients and eight outpatients who were screened for inclusion, 30 patients participated in the
study and 26 patients could be evaluated. Erosions, bone marrow edema, synovitis, and joint effusions were found
in 87%, 37%, 68%, and 58%, respectively, and 24% of patients had additional tenovaginitis. Arthritis affected only a
low number of joints per analyzed hand. All bones and joints could be affected, but synovitis and bone marrow
edema occurred predominantly in the proximal row of carpal bones, most frequently affecting the lunate bone.
The extent of inflammatory changes measured with the RAMRIS correlated significantly with the functional status
assessed with the validated German functional score questionnaire Funktionsfragebogen Hannover.
Conclusion: Low-grade arthritic changes on low-field MRI are frequent in patients with pure SSc. The features of
arthritis in SSc differ from rheumatoid arthritis. The distribution, the MRI pattern and the predilection for the lunate
bone raise the hypothesis that arthritis in SSc may be caused not only by immunological inflammation but also by
ischemic mechanisms.
Introduction
In the clinical evaluation of systemic sclerosis (SSc),
attention is predominantly given to changes of the skin,
Raynaud’s phenomenon and its complications, and inter-
nal organ involvement. While arthritis has been observed
in SSc [1], it is frequently considered to indicate an over-
lap between rheumatoid arthritis (RA) and SSc [2,3],
whereas joint pain in patients with sole SSc is commonly
regarded as non-inflammatory arthralgia caused by skin
tightness and flexion contractures [4].
Register studies [5,6] and retrospective clinical studies
including a meta-analysis of existing data [7] have
recently suggested that inflammatory arthritis may be an
underestimated problem in SSc. This suggestion could be
of therapeutic importance because disease-modifying
antirheumatic drugs available for inflammatory arthritis
might also be useful to delay or prevent joint damage and
loss of function in SSc patients.
We therefore performed a prospective magnetic reso-
nance imaging (MRI) study of the hands in patients with
SSc, excluding patients with clinical or immunological
signs suggesting an overlap with other forms of arthritis.
We aimed to determine the prevalence of MRI signs of
arthritis including synovitis, bone marrow edema, effusions,
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and erosions as well as to characterize the distribution of
joint involvement. MRI was chosen because it is an ima-
ging tool with high sensitivity for the detection of inflam-
matory joint changes, as has been demonstrated very well
in RA [8] and also in SSc [9,10].
Materials and methods
Consecutive patients with SSc treated as inpatients or
outpatients in our department between January 2010 and
March 2011 were considered for this study. Patients had
to fulfill the LeRoy criteria for limited cutaneous SSc or
diffuse cutaneous SSc [11]. We excluded patients with
the clinical picture of an overlap syndrome (such as
Sharp’s syndrome) or a clinical association with other
rheumatic diseases such as ankylosing spondylitis or RA.
We also excluded patients in whom antibodies against
U1-ribonucleoproteins or anti-citrullinated peptide anti-
bodies (ACPA) had been detected either within the pre-
vious year or when screened for enrolment. Outpatients
had to live within a radius of 50 km to be able to return
for the study assessments. To address the problem of
subclinical arthritis, the presence or absence of joint pain
or swelling was not considered for inclusion.
After obtaining written informed consent, the following
assessments were performed: tender and swollen hand
and finger joint counts; full skin status using the modified
Rodnan skin score; and functional assessment using the
German-language questionnaire Funktionsfragebogen
Hannover (FFbH) with values ranging from 0 to 100, the
latter reflecting completely normal function [12]. Use of
the FFbH is standard at our center and FFbH values can
be converted into health assessment questionnaire
(HAQ) values using the formula:
HAQ = 3.16 − (0.028× FFbH) .
The calculated HAQ is therefore also presented [13].
The erythrocyte sedimentation rate and, if not documen-
ted previously, ACPA were measured. Morbidity and
SSc-related treatments were also recorded.
Patients underwent low-field MRI (0.2 T, Esaote C-scan;
Esaote, Cologne, Germany) of the carpus and the metacar-
pophalangeal joints in either the more painful hand or, if
not applicable, the dominant hand [14,15]. A three-dimen-
sional, gradient-echo T1-weighted sequence, a fat-satu-
rated short-tau inversion recovery T2-weighted sequence,
and a second three-dimensional, gradient-echo T1-
weighted sequence were acquired after application of a
gadolinium-based contrast agent (Gadodiamide, Omnis-
can™; GE Healthcare, Munich, Germany). In consenting
patients, the other hand was measured after a time interval
of at least 1 day to allow for complete washout of the con-
trast agent.
Images were assessed systematically using two
approaches. In the first approach the Rheumatoid Arthri-
tis Magnetic Resonance Imaging Score (RAMRIS) [16,17]
developed for RA and high-field MRI was applied by two
independent investigators, and scores were calculated
using the average score of both investigators for each
item. Owing to the technical lack of fat suppression for
T1-weighted images in low-field MRI, synovitis was
assessed by comparing signal intensities of the synovium
before and after the application of Gadodiamide side by
side. Thickening of the synovium with enhancement after
application of the contrast agent was judged as synovitis,
which was assessed only if contrast agent could be
applied. Erosions were defined to be present if the con-
tour of the cortical bone was interrupted in at least two
anatomical planes and if enhancement of the defect with
Gadodiamide was detected. In series without application
of contrast agent, the first criterion was deemed suffi-
cient. The presence of bone marrow edema was scored as
definite if a hyperintense signal could be detected in the
short-tau inversion recovery sequence image and a
hypointense signal could be detected in the T1-weighted
image.
As the RAMRIS does not judge effusions and preselects
joints involved in RA, a second descriptive systematic
analysis for the presence of synovitis, bone marrow
edema, erosions, joint effusion, and tenovaginitis was per-
formed for the following areas: radiocarpal, ulnocarpal,
radioulnar, intercarpal and first carpometacarpal joints as
well as metacarpophalangeal joints 1 to 5. For bone mar-
row edema and erosions, bones of the carpus and meta-
carpus were analyzed separately (distal ulna, distal radius,
scaphoid, lunate, triquetral, pisiform, trapezium, trape-
zoid, capitate, hamate, bases of metacarpal bones 1 to 5,
heads of metacarpal bones 1 to 5, and bases of proximal
phalanges 1 to 5). Flexor and extensor tendons were ana-
lyzed for tenovaginitis.
Each MRI feature was classified as absent or question-
able, clearly present, or severe. If the increase in signal
intensity after contrast injection was obvious even in the
absence of a comparison with the baseline image, synovi-
tis was classified as severe. Severe erosions were defined
as defects occupying more than 50% of the bony surface.
Effusions were analyzed in the short-tau inversion recov-
ery sequence, with a convex contour of the fluid signal
within the joint capsule considered definite, and a disten-
tion of the overlying skin contour considered severe.
Bone marrow edema of more than 50% of the existing
bone area was considered severe. Examples for typical
findings for each assessment are shown in Figure S1 in
Additional file 1.
For statistical analysis, the Wilcoxon rank test or Fish-
er’s exact test were used where appropriate. Correlations
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were analyzed using Kendall’s tau rank test [18], which is
similar to Spearman’s Rho rank correlation test but does
not imply a linear correlation between values.
The study was approved by the ethics committee of
the University of Giessen.
Results
A total of 52 inpatients were screened for enrolment. Four
patients were excluded due to overlap with other rheu-
matic diseases, and three patients were excluded because
their clinical condition did not permit MRI measurements.
Seven patients were unable to participate due to organiza-
tional difficulties. Of the 38 inpatients enrolled in the
study, 27 agreed to undergo MRI measurements in one or
both hands. Eight outpatients were also found to be eligi-
ble, three of whom agreed to participate.
Three patients had to be excluded from the analysis
after acquisition of MRI measurements, because positive
results for ACPA became available in two of them and
the diagnosis had to be revised to Sharp’s syndrome in
the third patient. The signal quality of the MRI measure-
ments was inadequate for interpretation in one patient.
A total of 26 patients could therefore be analyzed, of
whom 12 agreed to measurements in both hands and the
other 14 only to measurements in one hand. A total of 38
hands could thus be examined. Owing to difficulties in
obtaining venous access, contrast agent could not be
applied in seven of the 38 MRI examinations. None of
the patients fulfilled either the current American college
of Rheumatology/European League Against Rheumatism
or the former American College of Rheumatology classi-
fication criteria for RA [19,20].
The characteristics of our group of patients and a
summary of the results, including the RAMRIS and the
functional FFbH and HAQ scores, are shown in Table 1.
The detailed RAMRI scores for each patient are pre-
sented in Table S1 in Additional file 2.
At the time of MRI examination, 10 patients received
immunomodulatory drug treatments: five patients were
being treated with methotrexate, one each with lefluno-
mide, mycophenolate, and etanercept, respectively, and
two patients were being treated with cyclophosphamide.
All patients on prednisolone took ≤ 5 mg/day. Iloprost
(Ilomedin™; Bayer Vital GmbH, Leverkusen, Germany)
was applied to 46% of patients at the time of MRI exami-
nation because of a clinical worsening of their Raynaud’s
syndrome. Nineteen patients were on long-term vasodi-
lating drugs (calcium channel blockers, bosentan and sil-
denafil), and three patients had concomitant
arteriosclerotic disease (two coronary heart disease, one
peripheral arterial disease).
When analyzing all measured hands, every MRI feature
of arthritis was observed in a high proportion of patients
(Table 2) even though 64% of all hands analyzed did not
exhibit any clinical pain or swelling in the joints assessed
by MRI. Only 21% of all hands did not show any signs of
current arthritis on MRI (synovitis, effusion, bone mar-
row edema).
While effusions and erosions were frequent, they were
rarely severe (Table 3; for reference, see also Figure S1 in
Additional file 1). Strong synovial enhancement was pre-
sent in 13% of analyzed patients. Severe bone marrow
edema occurred in 15% of patients, suggesting a strong
association of this feature of arthritis with SSc. In the
majority of patients, arthritis affected only a few joints
within one hand.
When analyzing the localization of affected joints and
bones, synovitis was found more frequently in the inter-
carpal joints than in the metacarpophalangeal joints
(Table 3), with severe synovitis occurring in up to 6% of
carpal joint areas. While bone marrow edema could
affect most bones of the carpus and metacarpus, it most
frequently and most severely affected the lunate, with a
definite edema occurring in 18% of lunate bones and
severe edema in 11%. The scaphoid and triquetrum
were also prone to bone marrow edema. The predilec-
tion of the proximal row of carpal bones for bone mar-
row edema was also reflected in the frequency of
erosions in these bones (Table 3). No synovitis could be
found in 27% of joint areas with bone marrow edema.
None of the patients has had previous severe trauma or
fractures of the distal forearm, carpal bones, metacarpal
bones, or fingers, and only one patient had a history of
occupational exposure to vibratory tools or machinery
(a construction worker who frequently drilled concrete).
In the latter patient, however, only the lunate and tri-
quetrum of the left hand each showed a small erosion
without bone marrow edema whereas the other carpal
bones of both hands showed no abnormality.
The RAMRIS validated for RA correlated moderately
with the overall functional joint status assessed by the
FFbH (correlation coefficient = -0.48, P = 0.002; Figure 1)
as well as the calculated HAQ scores (correlation coeffi-
cient = 0.48, P = 0.002). A summary score calculated from
the secondary systematic assessment correlated strongly
with the RAMRIS (correlation coefficient = 0.80, P <
0.0001). Clinical tender or swollen joint count results did
not match with MRI findings. The arthritis score was
more severe in patients with more widespread disease
involvement, reflected by the number of affected organ
systems (correlation coefficient = 0.43, P < 0.01), but there
was no association with the degree of skin involvement as
measured by the modified Rodnan skin score, systemic
inflammation as assessed by erythrocyte sedimentation
rate, disease duration, or age. The RAMRIS did not differ
between patients with short disease duration ≤ 3 years and
patients with longer-standing disease (mean ± standard
deviation RAMRIS, 6.3 ± 4.3 vs. 6.6 ± 5.0, P = 0.918).
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Table 1 Patient characteristics
Parameter All SSc (n = 26) Diffuse cutaneous SSc (n = 6) Limited cutaneous SSc (n = 20)
Age (years) 56 ± 13 (32 to 75) 50 ± 9 (40 to 66) 46 ± 14 (32 to 75)
Sex (% female) 77 67 80
Disease duration (years) 7.9 ± 5.3 (1 to 19) 7.7 ± 6.0 (3 to 19) 8.0 ± 5.2 (1 to 18)
Modified Rodnan skin score 8.3 ± 6.1 (2 to 19) 16.3 ± 3.3 (12 to 19) 5.8 ± 4.3† (2 to 18)
Organ and tissue involvement
Pulmonary fibrosis 11 (42) 6 (100) 5 (25)**
Pulmonary hypertension 5 (19) 3 (50) 2 (10)
Cardiac involvement 6 (23) 1 (17) 5 (25)
Gastrointestinal involvement 2 (8) 1 (17) 1 (5)
Active digital ulcer 7 (27) 0 (0) 7 (30)
History of digital ulcer 16 (62) 4 (83) 12 (55)
Arteriosclerotic disease 3 (12) 0 (0) 3 (15)
ESR (mm/hour) 19 ± 14 28 ± 20 16 ± 11
Antinuclear antibody positivity 23 (89) 5 (83) 18 (90)
Anti-centromere antibody 11 (42) 0 (0) 11 (55)*
Anti-Scl70 antibody 9 (35) 2 (33) 7 (35)
Medication
Immunomodulatory druga 10 (38) 2 (33) 8 (40)
Steroids 6 (23) 1 (17) 5 (25)
Iloprost 12 (46) 3 (50) 9 (45)
Calcium-channel blockers 9 (35) 2 (33) 7 (35)
Betablockers 1 (4) 0 (0) 1 (5)
Bosentan 7 (27) 3 (50) 4 (20)
Sildenafil 3 (12) 0 (0) 3 (15)
Low-dose aspirin 5 (19) 0 (0) 5 (25)
RAMRIS 6.5 ± 4.7 (0 to 14) 5.4 ± 4.1 (1 to 12) 7.0 ± 5.0 (0 to 14)
Radiographs of the hands 21 (81) 4 (67) 17 (85)
Signs of arthritis 2 (10) 0 (0) 2 (12)
Acroosteolysis 9 (43) 2 (50) 7 (41)
Soft-tissue calcifications 11 (52) 1 (25) 10 (59)
FFbH (% functional capacity) 68.7 ± 22.8 (33 to 100) 58.2 ± 25.2 (39 to 100) 71.9 ± 21.7 (33 to 100)
Health Assessment Questionnaireb 1.24 ± 0.64 (0.36 to 2.25) 1.54 ± 0.7 (0.36 to 2.08) 1.15 ± 0.61 (0.36 to 2.25)
Data presented as mean ± standard deviation (range) or n (%). Only the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) for the clinically
dominantly affected hand was analyzed. Percentages were rounded. ESR, erythrocyte sedimentation rate (Westergren’s method); FFbH, Funktionsfragebogen
Hannover (German-language standardized assessment questionnaire on physical function); SSc, systemic sclerosis. Significant differences: *P < 0.05 and **P < 0.01
between the groups with limited and diffuse skin disease as assessed by Fisher’s exact test; †P < 0.01 as assessed by the Mann-Whitney U test. All other
comparisons were nonsignificant. aIncluding methotrexate, leflunomide, mycophenolate, etanercept, and cyclophosphamide. bValues calculated from the FFbH
using the formula: HAQ = 3.16 - (0.028 × FFbH)).
Table 2 Proportion of hands showing different features of arthritis on magnetic resonance imaging
Erosion Bone marrow edema Synovitis Joint effusion Tenovaginitis
Signs of arthritis
Not present/indeterminate 13 63 32 42 76
Present 87 37 68 58 24
Severe 3 16 13 0 0
Affected joints in affected hands 2.2 ± 1.6 (1 to 6) 1.6 ± 1 (1 to 4) 4.1 ± 2.6 (1 to 9) 4.2 ± 2.6 (1 to 10) N/A
Data presented as percentage or mean number ± standard deviation (range). For definition of definite or severe please refer to Materials and methods. N/A, not
applicable.
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There was also no correlation between immunosuppres-
sive drug treatment, iloprost treatment, long-term vasodi-
lating drug treatment, b-blocker use, low-dose aspirin use,
or concomitant arteriosclerotic disease and the presence
of MRI features of arthritis. Neither was affection of the
lunate bone correlated with arteriosclerosis or the use of
vasodilating drugs, b-blockers or low-dose aspirin.
Radiographs of the hands were obtained as part of the
diagnostic work-up in 21 of the 26 patients (81%; Table
1). Two patients had radiographic changes of the lunate.
One of these patients had a small erosion that corre-
sponded to the erosion seen on low-field MRI. The
other patient exhibited small cystic changes of both
lunate bones but no definitive erosions on X-ray, whereas
low-field MRI clearly showed bilateral lunate erosions. In
all other patients with lunate erosions on MRI, no
abnormalities were detected by X-ray scan. Of note, none
of the patients with bone marrow edema of the lunate
bone had radiographic abnormalities. Acroosteolysis and
extraarticular soft-tissue calcifications were observed in
43% and 52% of the radiographs, respectively (Table 1).
The presence and severity of MRI features of arthritis,
however, were not correlated with the finding of either
acroosteolysis or calcifications.
Discussion
This prospective systematic low-field MRI study shows
that subclinical arthritis of the carpus and metacarpus is
a frequent manifestation in patients with SSc, which is
underestimated by clinical examination as well as plain
radiographs. The relevance of this observation is under-
lined by the correlation of a quantitative assessment of
arthritic changes, the RAMRIS, with validated functional
assessments, the FFbH and HAQ. The arthritis score is
also associated with severity of disease estimated by the
number of affected organ systems.
The presence of arthritis in SSc has been suggested in
large register studies [5,6]. A retrospective cohort analysis
with supplementary meta-analysis from our group also
supports a high prevalence of clinical and erosive arthritis
as a genuine feature of SSc [7]. Register cohorts have the
drawback that data are frequently collected by nonrheu-
matologists, resulting in a high heterogeneity in classifica-
tion of joint findings [5]. Furthermore, a definite
differentiation between overlap syndromes and pure SSc is
difficult within register studies, retrospective approaches
or meta-analyses [7].
MRI is considered a very sensitive method for the
detection of arthritis. High-field MRI has thus far been
used to examine hand joints in SSc patients in two
smaller studies. One retrospective study on 17 patients
with joint pain and SSc observed inflammatory changes
in 59% of patients [9]. In this study, bone marrow
edema was even more prominent (53%) than in our
cohort (37%), whereas the proportion of patients with
erosions was much lower (41%) compared with our
study (87%). Unfortunately, no details are provided on
the localization of bone marrow edema in the different
patients [9]. Another prospective study analyzed 17
patients with arthralgias and SSc by ultrasound, eight of
whom also underwent MRI [10]. Joint synovitis was
found by ultrasound in one of 17 patients initially, in
three of 13 patients after 6 months, and in eight of eight
patients analyzed by MRI. Of these eight patients, five
also exhibited bone marrow edema and six patients had
erosions [10]. Ultrasound thus appears to underestimate
Table 3 Distribution of magnetic resonance imaging
findings in individual joints and bones of the hand
Synovitis Joint effusion
Definitive Severe Definitive Severe
Joint
Radiocarpal 19 3 8 -
Radioulnar 23 - - -
Ulnocarpal 48 6 - -
Intercarpal 52 3 47 -
Carpometacarpal joint 1 6 - 3 -
Metacarpophalangeal
joint 1
13 - 11 -
Metacarpophalangeal
joint 2
6 - 3 -
Metacarpophalangeal
joint 3
23 - - -
Metacarpophalangeal
joint 4
16 - 5 -
Metacarpophalangeal
joint 5




Definitive Severe Definitive Severe
Bone
Ulna/radius - - 3 -
Scaphoid 3 - 13 -
Lunate 18 11 45 3
Triquetral 8 - 50 -
Pisiform - - - -
Trapezium 5 3 13 -
Trapezoid - - 5 -
Capitate 3 - 24 -
Hamate - - 3 -
Metacarpal base 1 to 5 2 1 2 -
Metacarpal head 1 to 5 1 - 8 -
Phalangeal base 1 to 5 - - 2 -
For each magnetic resonance imaging feature, frequencies of definite and
severe manifestation are indicated as a percentage. -, not present. Joint
effusion, bone marrow edema and erosions could be determined in 38 hands
from our 26 patients. Synovitis could only be assessed in 31 hands, due to
lack of venous access for the application of contrast agent.
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arthritis manifestations in SSc even in patients with clin-
ical arthralgias.
The high sensitivity of the MRI technique, the relatively
large number of patients for a single center and the inclu-
sion of patients independent of clinical arthralgia or joint
swelling as well as the stringent exclusion of known arthri-
tis-associated diseases are specific strengths of our study
for the determination of a point prevalence of arthritis in
SSc in comparison with the other studies. A drawback of
our study is the absence of a healthy control group, since
erosions can also be observed in healthy subjects [21]. Even
though we used a very stringent definition of erosion, the
prevalence of erosions may thus be overestimated. On the
contrary, the low-field technique underestimates bone mar-
row edema compared with high-field MRI [14], which may
explain the difference in comparison with the results of
Low and colleagues [9]. The failure to inject intravenous
contrast agent in 18.5% of the 38 MRI examinations leads
to underestimation of synovitis in the RAMRIS. The multi-
tude of arthritis-associated MRI findings and the asso-
ciation of quantitative arthritis assessments with the
functional score are arguments for the overall validity of
our findings. Another drawback is that 35% of eligible
patients declined participation, even though the positioning
in the low-field MRI is more tolerable than in high-field
MRI. The overall disease severity of SSc in these patients
was comparable, but this dysbalance may bias our findings.
The prevalence and severity of erosions, bone marrow
edema, and synovitis in our cohort with longstanding SSc
are comparable with studies on patients with early RA
[22]. In longstanding RA, the severity of inflammatory
and destructive changes usually increases and affects
more joints, thus leading to more severe MRI findings
than those observed in our study [8]. Owing to the fact
that the patients in our study did not fulfill any classifica-
tion criteria of RA and that the detected arthritic changes
were relatively mild despite long-standing disease without
disease-modifying anti-rheumatic drug treatment in the
majority of cases, we conclude that arthritis in SSc does
not reflect an overlap syndrome with RA [2,3], but repre-
sents a genuine disease manifestation.
The high prevalence of bone marrow edema in our
cohort is of specific interest since bone marrow edema in
RA usually heralds erosions [15,22]. The same indication
appears to be true for arthritis in SSc since the finding of
bone marrow edema was frequently associated with ero-
sions in our study. The predilection of bone marrow
edema and erosions for the lunate and other bones of the
proximal row of carpals is noteworthy and reminiscent of
early osteonecrosis.
Figure 1 Correlation of the arthritis score with global function. Correlation of the Rheumatoid Arthritis Magnetic Resonance Imaging Score
(RAMRIS) with global function assessed by the German Funktionsfragebogen Hannover (FFbH) questionnaire.
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This finding raises the hypothesis that not only an
autoimmune process but also ischemia on the basis of
the characteristic microangiopathy of SSc and the fre-
quent stenosis of arterial vessels of the wrist in patients
with SSc [23,24] may play a role in SSc arthritis and its
predilection for the lunate bone. Along this line, four
cases have been published [25,26] that illustrate an asso-
ciation between osteonecrosis of the lunate bone and
SSc with severe Raynaud’s phenomenon, the clinical
hallmark of ischemia in SSc. In addition, the severity of
Raynaud’s phenomenon has been associated previously
with the development of erosive arthritis in SSc [27].
The prominent affection of the lunate bone and the
high severity of Raynaud’s phenomenon in the majority
of our patients - as indicated by the high proportion of
patients complaining of clinical deterioration (62%), the
need for intravenous iloprost despite long-term use of
oral vasodilators, and the high proportion of current or
previous digital ulcers - thus fit very well with the
hypothesis that SSc arthritis is triggered by reactions to
ischemia in the context of severe Raynaud’s phenom-
enon [28] in addition to immunological mechanisms.
Conclusion
In summary, arthritis characterized by mild synovitis, bone
marrow edema with a predilection for the lunate bone,
mild effusions, and low-grade erosions is a clinically
underestimated but frequent, genuine feature of SSc. The
pattern of arthritis does not resemble RA. We hypothesize
that an ischemic component reflected by severe Raynaud’s
phenomenon may be a key trigger for this type of joint
manifestation. Further studies on a larger number of
patients are needed to further verify this hypothesis, which
would then open up new avenues for the treatment of
arthritis in SSc.
Additional material
Additional file 1: Figure S1 showing typical examples of arthritis
features on low-field MRI. This figure provides typical examples of
synovitis, bone marrow edema, erosions, joint effusion, and tenovaginitis
on low-field MRI. (A) Synovitis: T1-weighted gradient-echo sequence
before (1, 3) and after (2, 4) application of Gadodiamide shows definite
(*) synovitis of the intercarpal and radioulnar joints (1, 2) and the third
metacarpal joint (3, 4) and severe (arrows) synovitis with synovial
thickening and contrast enhancement of the radiocarpal and ulnocarpal
joints (1, 2). (B) Bone marrow edema (arrows) affecting < 50% of the
bone marrow area (1, 2) and severe edema affecting > 50% of the bone
marrow area (3, 4) appear as hypointense areas in T1-weighted images
(1, 3) and hyperintense areas in T2-weighted short-tau inversion recovery
images (2, 4). (C) Erosion: T1-weighted gradient echo sequence before (1)
and after (2) application of Gadodiamide show erosions (arrows) of
different sizes. A severe erosion is shown in coronary (3) and transverse
(4) sections. (D) Effusion: T2-weighted short-tau inversion recovery image
visualizes hyperintense fluid signals (arrows) of normal joint fluid (1),
definite effusion (2, 3), and severe effusion (4, 5) as well tenovaginitis of
the flexor tendons grade 2 (6).
Additional file 2: Table S1 presenting a summary of the RAMRIS.
This table provides an overview of the RAMRIS per patient. N/A, not
applicable due to lack of venous access for the injection of contrast
agent.
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